2022
DOI: 10.1097/yic.0000000000000417
|View full text |Cite
|
Sign up to set email alerts
|

The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?

Abstract: Antipsychotic polypharmacy in psychotic disorders is widespread despite international guidelines favoring monotherapy. Previous evidence indicates the utility of low-dose partial dopamine agonist (PDAs) add-ons to mitigate antipsychotic-induced metabolic adverse effects or hyperprolactinemia. However, clinicians are often concerned about using PDAs combined with high-potency, full dopaminergic antagonists (FDAs) due to the risk of psychosis relapse. We, therefore, conducted a literature review to find studies … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
11
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 11 publications
(11 citation statements)
references
References 106 publications
0
11
0
Order By: Relevance
“…Prior studies have examined how adding Aripiprazole to another, more potent D2 antagonist can cause a relapse in psychotic symptoms; however, few studies have investigated the inverse relationship or mechanism. Those that have proposed mechanisms typically refer to Aripiprazole’s partial agonist activity as the causative factor, rather than an impediment to antipsychotic binding, which we have described (Adan-Manes and Garcia-Parajua, 2009; Lippi et al , 2022). While this interaction could be potentially problematic with oral formulations of these medications, it becomes particularly more so when using depot formulations, as seen in the above patient, as Ms. A did not respond to her previously effective dose of Paliperidone.…”
Section: Discussionmentioning
confidence: 85%
See 1 more Smart Citation
“…Prior studies have examined how adding Aripiprazole to another, more potent D2 antagonist can cause a relapse in psychotic symptoms; however, few studies have investigated the inverse relationship or mechanism. Those that have proposed mechanisms typically refer to Aripiprazole’s partial agonist activity as the causative factor, rather than an impediment to antipsychotic binding, which we have described (Adan-Manes and Garcia-Parajua, 2009; Lippi et al , 2022). While this interaction could be potentially problematic with oral formulations of these medications, it becomes particularly more so when using depot formulations, as seen in the above patient, as Ms. A did not respond to her previously effective dose of Paliperidone.…”
Section: Discussionmentioning
confidence: 85%
“…Aripiprazole has been proven effective in treating psychosis with the added benefit of fewer extrapyramidal, anticholinergic, or antihistaminergic side effects than FGAs (Stahl, 2020). It is thought to act as a "dopamine system stabilizer" by reducing dopamine in regions with overactive dopamine activity (mesolimbic system), while simultaneously increasing dopamine in regions with underactive dopamine activity (mesocortical system), demonstrating what Stahl coined as "Goldilocks actions" (Stahl, 2001;Lippi et al, 2022). Theoretically, this would explain Aripiprazole's ability to improve both the positive and negative symptoms of schizophrenia, as well as potentially enhance cognitive function.…”
Section: Introductionmentioning
confidence: 99%
“…29 A differential diagnosis between drug-induced and primary psychoses should be assessed in all older patients with polypharmacy. 30,31 The mean time of symptom onset is approximately 11.5 days. However, psychiatric manifestations may appear just 3-4 days after treatment initiation.…”
Section: From the Pathophysiological Bases To The Clinical Practicementioning
confidence: 99%
“…The use of APP in clinical practice may sometimes be justified also by the desire to improve the therapeutic response (Lahteenvuo and Tiihonen, 2021). However, even in this case, it is known that particular care must be taken when combining a partial dopaminergic agonist and a full D2 receptor antagonist, which may increase the risk of clinical relapse or worsening of psychotic symptoms ( Lippi et al , 2022 ). The relevant gap between evidence and routine practice, therefore, needs to be further investigated.…”
Section: Introductionmentioning
confidence: 99%